MindRank
PrivateLast Round
Series B
Jul 10, 2026
Total Funding Raised
$82M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
MindRank operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series B round in July 2026.
MindRank is a clinical-stage drug discovery company that uses its proprietary artificial intelligence (AI) platforms to accelerate the development of small molecule medicines.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MindRank Comparables
Compare MindRank with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genesis Molecular AI | 87% | |
| Galixir | 85% | |
| Guangzhou Fermion Technology Co., Ltd. | 85% |
For institutional investors. Book with your work email.
MindRank Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 10, 2026 | ||||
| Series A Extension | Jul 18, 2023 | ||||
| Series A | Dec 16, 2021 | ||||
| Seed | May 21, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
MindRank Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Huagai Capital | Series A |
| Sherpa Healthcare Partners | Series A, Seed |
| 松禾资本 (Green Pine Capital Partners) | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 157% MoM.
- Jul 25, 2026
Monthly visitors increased 68% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 28, 2026
MindRank Ltd. and Zhejiang Sunshine Mandi Pharmaceutical Co. entered a strategic commercialization agreement for MDR-001 covering mainland China, Hong Kong and Macau, with exclusive commercialization services planned after regulatory approval and launch, in China on Sep 28th '26.
For institutional investors. Book with your work email.
MindRank Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MindRank's valuation, stock price, and market status.
Is MindRank a public or private company?
MindRank is a private company.
What is the current stock price of MindRank?
MindRank is a private company, so its shares have no public market price. Caplight tracks MindRank's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MindRank worth (valuation)?
Valuation information for MindRank is not publicly available.
Can I buy MindRank stock?
MindRank shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MindRank's last funding round?
MindRank's most recent funding round was Series B on July 10, 2026.
Who are the main investors in MindRank?
Key investors in MindRank include Huagai Capital, Sherpa Healthcare Partners, 松禾资本 (Green Pine Capital Partners).
Will MindRank IPO soon?
No public IPO plans have been announced for MindRank.
How can I track MindRank secondary market activity?
Caplight tracks bids, offers, and trades in MindRank's shares on secondary markets.